BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16530198)

  • 1. The effects of analytical factors on second trimester risk estimations.
    Serdar MA; Tütüncü L; Olgun A; Haşimi A; Ozgurtaş T; Erbil MK
    Int J Gynaecol Obstet; 2006 Apr; 93(1):28-32. PubMed ID: 16530198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum screening in Ontario using the triple marker test.
    Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
    J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.
    Akbas SH; Ozben T; Alper O; Ugur A; Yücel G; Lüleci G
    Clin Chem Lab Med; 2001 Jun; 39(6):487-90. PubMed ID: 11506458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy.
    Rausch DN; Lambert-Messerlian GM; Canick JA
    West J Med; 2000 Sep; 173(3):180-3. PubMed ID: 10986181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prenatal serum screening of aneuploidy and of neural tube defects in the second trimester of pregnancy among the population of Luxembourg. Evaluation of risk by the triple test (AFP+THCG+UE3)].
    Thix J
    Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(1):25-9. PubMed ID: 9303823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum screening of Palestinian women in the West Bank.
    Husseini A; Akkawi M
    East Mediterr Health J; 2005 Jul; 11(4):824-7. PubMed ID: 16700399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects.
    Jaques AM; Collins VR; Haynes K; Sheffield LJ; Francis I; Forbes R; Halliday JL
    J Med Screen; 2006; 13(1):8-13. PubMed ID: 16569299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trisomy 18 fetuses with cystic hygroma linked to positive maternal serum Down's syndrome Triple test screening result.
    Celentano C; Guanciali-Franchi PE; Liberati M; Prefumo F; Palka G; Rotmensch S
    J Med Screen; 2005; 12(4):203. PubMed ID: 16417699
    [No Abstract]   [Full Text] [Related]  

  • 15. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening.
    Huang T; Owolabi T; Summers AM; Meier C; Wyatt PR
    Am J Obstet Gynecol; 2005 Aug; 193(2):395-403. PubMed ID: 16098861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Noninvasive serum test for prenatal detection of Down syndrome, other chromosome abnormalities and open neural tube defects--a prospective study].
    Zwahr C; Voss P; Kistner G
    Geburtshilfe Frauenheilkd; 1994 Jun; 54(6):355-61. PubMed ID: 7522195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The triple-serum test for detection of Down syndrome and neural tube defects; the problem of a risk assessment test].
    van den Boer-van den Berg JM; Dupuis HM
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1286-9. PubMed ID: 7688445
    [No Abstract]   [Full Text] [Related]  

  • 20. Maternal serum screening for birth defects: results of a Connecticut regional program.
    Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
    Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.